- Home
- Anticoagulation Academy
Professor Gregory Lip highlights the benefits of dabigatran (NOACs) for AF patients requiring anticoagulation therapy while citing evidence from some key clinical trial studies and real-world data of dabigatran showing a significant relative risk reduction in ischemic stroke, systemic embolism, intracranial hemorrhage and all-cause mortality when compared to OACs or other NOACs. The availability of idarucizumab, a specific dabigatran reversal agent adds greater control and is an important factor in oral anticoagulation therapy.
Professor Gregory Lip highlights the benefits of dabigatran (NOACs) for AF patients requiring anticoagulation therapy while citing evidence from some key clinical trial studies and real-world data of dabigatran showing a significant relative risk reduction in ischemic stroke, systemic embolism, intracranial hemorrhage and all-cause mortality when compared to OACs or other NOACs. The availability of idarucizumab, a specific dabigatran reversal agent adds greater control and is an important factor in oral anticoagulation therapy.
